REG - Oxford Biomedica PLC - 2025 Annual General Meeting notification

Oxford BioMedicaAnnouncement

Mon 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb4646Ga&default-theme=true

RNS Number : 4646G  Oxford Biomedica PLC  28 April 2025

 

OXB

2025 Annual General Meeting notification

 

Oxford, UK - 28 April 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, gives notice that the Notice of
Annual General Meeting ("AGM") together with a copy of the 2024 Annual report
and accounts are being sent to shareholders today. These documents are
available on the "Investors" section of the Group's website at www.oxb.com
(http://www.oxb.com/) .

In accordance with UK Listing rule 14.3.6R, a copy of the Notice of AGM has
been submitted to the Financial Conduct Authority for publication through the
National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . The Company intends
to hold its AGM on Wednesday 11 June 2025 at its offices at Windrush Court,
Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

 

-Ends-

 

Enquiries:

 

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
(mailto:cosec@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAIPMBTMTBTBLA